Nevertheless, selinexor‐Vd did result in an increased rate of grade ≥3 thrombocytopenia compared to Vd in BOSTON, associated with the different causative mechanisms of thrombocytopenia with selinexor and bortezomib [101, 102]; while bortezomib results in transient, cyclical decreases in platelet counts due to inhibition of platelet budding from megakaryocytes, selinexor‐induced thrombocytopenia arises from inhibition of thrombopoietin signalling early during megakaryopoiesis. The gene discussed is THPO; the disease is Thrombocytopenia.